Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on May 20, 2019
Patents are an important driver of prescription drug innovation. Recently, manufacturer practices under the current patent system have come under scrutiny for blocking or delaying the entry of generic or biosimilar drugs into the market. The development of novel therapies plays a critical role in treating, and in some cases eradicating, debilitating and costly diseases. However, the high cost of prescription drugs continues to challenge patients and the health care system. The sale of biosimilar and generic drugs offers a promising opportunity to promote prescription drug affordability through competition. During this webinar, panelists explored the relationship between patents, prices, and patient access.